Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck's HPV vaccine Gardasil 9 meets efficacy goals in trial involving Japanese males 16-26 years old, reducing HPV ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

According to GlobalData, the recombinant vesicular stomatitis virus – Zaire Ebola virus (rVSV-ZEBOV) vaccine is marketed by Merck under the name Ervebo. It has been available in the US and EU ...

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...

“A decade after the first approval of GARDASIL 9, Merck continues to evaluate this important vaccine in additional patient populations and remains committed to helping prevent certain HPV ...